M.D. Anderson Cancer Center
To find out if the combination of BMS-986504 plus neoadjuvant/adjuvant chemotherapy and surgery (Cohort 1) or BMS-986504 plus standard of care chemotherapy (Cohorts 2 and 3) can help to control pancreatic cancer.
Primary Objectives * Cohort 1: To evaluate the safety and tolerability of BMS-986504 in combination with neoadjuvant/adjuvant chemotherapy and as maintenance therapy in participants with resectable/borderline resectable PDAC. Major pathological response (MPR) and incidence, severity and duration of pre- and post-operative complications (e.g. delay of surgery, inability to get surgery, type and rate of postoperative complications \[like pancreatic fistula\], rate of resection for borderline participants) will be evaluated. * Cohorts 2 and 3: To evaluate the safety, tolerability and efficacy of…
Eligibility Criteria * Age ≥18 years. * Homozygous MTAP deletion detected by NGS. Test can be performed on an archival tissue collected within 6 months from study enrollment and on blood samples. * ECOG performance status 0-1. * Histologically or cytologically confirmed pancreatic ductal adenocarcinoma (PDAC) * Adequate organ and marrow function as defined below * Hemoglobin ≥9.0 g/dL with no packed red blood cell transfusions in the past 7 days. * Absolute neutrophil count (ANC) ≥1.5 x 10⁹/L. * Platelet count ≥100 x 10⁹/L with no platelet transfusions in the past 7 days. * Total bil…
Given by po
Given by IV
Given by IV
Given by iv
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.